Concepedia

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola,

The Lancet Oncology · 2016 · 939 citations · 25 references

DOIFull text

Open access

Concepts

References

25

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

, , +17

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text

, , +14

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · The Lancet · 2008 · 3K citations

, , +11

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg, Ian D. Davis, Jozef Mardiak et al. · Journal of Clinical Oncology · 2010 · 2.5K citations · Full text

, , +17